洲际航天科技 01725.HK 深 沪
已收盘 11-14 16:10:00
0.820
0.000
0.00%
华盛通- 最 高0.870
- 今 开0.830
- 成交量 741.76万股
- 最 低 0.810
- 昨 收 0.820
- 总市值 4.95亿
- 52周最高 1.450
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 0.580
- 委 比 -5.09%
- 总股本 6.04亿
- 历史最高 1.210
- 量 比 1.80
- 振 幅 7.32%
- 历史最低 0.480
- 每 手 200
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多港股公告精选｜腾讯三季度盈利超600亿元 中芯国际前三季收入同比增约两成
①腾讯三季度盈利超600亿元，各项业务增速有多快？ ②中芯国际前三季收入同比增约两成，四季度预期如何？
11-13 20:33
洲际航天科技(01725)附属港航科与中科星桥订立战略合作协议，共同推进中科星桥空天地一体化产业项目
洲际航天科技(01725)发布公告，于2025年11月11日，本公司全资附属公司港...
11-13 17:23
洲际航天科技(01725.HK)发布公告，陈有安先生及卢华胜先生已获委任为执行董事，自2025年11月12日起生效
洲际航天科技(01725.HK)发布公告，陈有安先生及卢华胜先生已获委任为执行董事，自2025年11月12日起生效。
11-13 06:50
洲际航天科技（01725.HK）11月4日收盘跌6.25%，主力资金净流出139.79万港元
证券之星消息，截至2025年11月4日收盘，洲际航天科技(01725.HK)报收于0.9港元，下跌6.25%，成交量471.66万股，成交额435.82万港元。
11-04 18:31
TeraWulf Inc. Announces Upsize and Pricing of $900 Million Convertible Notes Offering
TeraWulf Inc. announced the issuance of $900 million 0.00% convertible senior notes due 2032, with a 37.5% conversion premium. The offering is expected to close on October 31, 2025, raising approximately $877.6 million ($999.7 million if the over-allotment option is exercised). Proceeds will fund a data center campus in Texas and general corporate purposes. The notes are senior unsecured obligations, with no regular interest, and will be converti...
10-30 01:54
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
<p>Akebia Therapeutics announced it will not initiate the VALOR clinical trial for vadadustat to treat anemia in late-stage CKD patients not on dialysis, following feedback from the U.S. FDA. The FDA indicated the trial would require a significantly larger patient population, more time, and higher costs. Akebia is disappointed but believes this decision aligns with shareholders' interests. The company remains committed to making Vafseo (vadadusta...
10-28 20:30
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
Revolution Medicines announced that the FDA has granted Orphan Drug Designation to daraxonrasib for treating pancreatic cancer. Daraxonrasib is a RAS(ON) multi-selective inhibitor currently in a global Phase 3 trial for second-line metastatic PDAC. The company plans additional Phase 3 trials for first-line and adjuvant treatments. Pancreatic cancer, highly RAS-addicted, has limited therapy options. Orphan Drug status offers incentives like tax cr...
10-27 12:00
